Opinion

Video

Novel Intravitreal Injections: Faricimab and Aflibercept 8mg for the Treatment of Retinal Diseases

Author(s):

Aleksandra Rachitskaya, MD,Jordan Graff, MD, FACS

Panelists discuss how novel intravitreal agents faricimab and high-dose aflibercept 8mg offer potential advantages in treating retinal diseases through their extended durability and dual mechanism of action.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(mage credit: Ophthalmology Times) S. Robert Levine, MD, on the DRD Cure Accelerator: A global moonshot for retinal disease
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
Related Content
(Image credit: AdobeStock/InkInvent) FDA clears path for US IDE study of Myra Vision’s titratable glaucoma therapy
August 14th 2025

FDA clears path for US IDE study of Myra Vision’s titratable glaucoma therapy

3 Things You Should Know About the GA Pipeline
August 14th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

(Image credit: AdobeStock/zabhie) AI applications in cataract surgery: A surgeon’s perspective
August 14th 2025

AI applications in cataract surgery: A surgeon’s perspective

Patient-Centered Treatment Strategies in the Management of nAMD and DME
August 14th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

(Image credit: Wills Eye Hospital) Wills Eye Hospital names Julia A. Haller, MD, as new chief executive officer
August 14th 2025

Wills Eye Hospital names Julia A. Haller, MD, as new chief executive officer

(Image credit: AdobeStock/Bonsales) Q&A: Natalie Afshari, MD, FACS, on-label pediatric IOLs: turning advocacy into access
August 14th 2025

Q&A: Natalie Afshari, MD, FACS, championing on-label pediatric IOLs: turning advocacy into access

© 2025 MJH Life Sciences

All rights reserved.